Structural Evaluations of a Selective Human STINGA230 Agonist and Its Use in Macrophage Immunotherapies

By sjmartinez • May 15, 2024

Tang Z, Zhao J, Li Y, Tomer S, Selvaraju M, Tien N, Sun D, Johnson DK, Zhen A, Li P, Wang J. Structural Evaluations of a Selective Human STING^A230 Agonist and Its Use in Macrophage Immunotherapies. ACS Med Chem Lett. 2024 Apr 12;15(5):653-658. doi: 10.1021/acsmedchemlett.4c00048. PMID: 38746895; PMCID: PMC11089548.

Tags: Hematology/Oncology, Publications

Goserelin 3-month depot shows non-inferiority to the monthly formulation in U.S. patients with premenopausal breast cancer: a real-world evidence study

McCann KE, Osman N, Cannon J, Brent L, Wang Y, Tepsick J, Mandora PV, Miller V, Martin N, Kaklamani VG. Goserelin 3-month depot shows non-inferiority[...]

A plain language summary of quality of life with sacituzumab govitecan treatment in the TROPiCS-02 study in participants with breast cancer (HR-positive/HER2-negative)

Rugo HS, Schmid P, Tolaney SM, Marmé F, Bardia A, Spears PA, Cortés J. A plain language summary of quality of life with sacituzumab govitecan[...]

Surrogate endpoints for overall survival in randomized clinical trials testing antibody-drug conjugates

Pala L, Merlo F, Sala I, Pagan E, Oriecuia C, Specchia C, Catania C, Cocorocchio E, Laszlo D, Ceresoli G, Locatelli M, De Pas T,[...]